1 | × | 6,709 |
2 | hz/100 | 33 |
3 | mg/amlodipine | 16 |
4 | mg/aml | 10 |
5 | mg/acetaminophen | 8 |
6 | w/100 | 8 |
7 | mg/indapamide | 7 |
8 | mg/pio | 6 |
9 | mg/bza | 5 |
10 | mg/drospirenone | 5 |
11 | episodes/10,000 | 4 |
12 | hz/15 | 4 |
13 | hz/20 | 4 |
14 | mg-simvastatin | 4 |
15 | mg/dng | 4 |
16 | ∶ | 4 |
17 | cm/6 | 3 |
18 | hz/ | 3 |
19 | kg/8 | 3 |
20 | mg/ezetimibe | 3 |
21 | mg/kg+mid | 3 |
22 | nm-1 | 3 |
23 | t/128 | 3 |
24 | wk-1 | 3 |
25 | +amoxicillin | 2 |
26 | /dynes | 2 |
27 | /ejection | 2 |
28 | 000-1 | 2 |
29 | 1-type | 2 |
30 | 1/group | 2 |
31 | 2,5-carbodianions | 2 |
32 | 486+pg | 2 |
33 | =2.88 | 2 |
34 | a.m.-10 | 2 |
35 | anti-tarc+100 | 2 |
36 | bresse | 2 |
37 | cm/2 | 2 |
38 | dn001 | 2 |
39 | groups-an | 2 |
40 | h-driving | 2 |
41 | hz/200 | 2 |
42 | hz/50 | 2 |
43 | l-name-epicatechin | 2 |
44 | lx:0.5 | 2 |
45 | mft/d | 2 |
46 | mg+clopidogrel | 2 |
47 | mg+hyd | 2 |
48 | mg/benserazide | 2 |
49 | mg/dienogest | 2 |
50 | mg/drsp | 2 |
51 | mg/every | 2 |
52 | mg/lidocaine | 2 |
53 | mg/lisinopril | 2 |
54 | mg/pravastatin | 2 |
55 | mg/rizatriptan | 2 |
56 | mg/simvastatin | 2 |
57 | mg/sumatriptan | 2 |
58 | mg/valsartan | 2 |
59 | miu/mg98 | 2 |
60 | months/ | 2 |
61 | n-acetylglucosamine-transferase | 2 |
62 | nm-32.8 | 2 |
63 | nm/20 | 2 |
64 | p.m.-6 | 2 |
65 | post-addendum | 2 |
66 | rhtarc+20 | 2 |
67 | subjects/ | 2 |
68 | thiazole-4,11-diones | 2 |
69 | vs.low-dose | 2 |
70 | w/3 | 2 |
71 | wk-6 | 2 |
72 | yù | 2 |
73 | °p-timi | 2 |
74 | ×/daily | 2 |
75 | х | 2 |
76 | +/-18.9 | 1 |
77 | +74.0 | 1 |
78 | -25385tt | 1 |
79 | -3-alkylideneindolin-2-ones | 1 |
80 | -7,7-dimethyl-5-oxo-4h-chromene-3-carbonitrile | 1 |
81 | -melatonin | 1 |
82 | -o-oleoyl- | 1 |
83 | .phase | 1 |
84 | /glycopyrrolate | 1 |
85 | /hapless | 1 |
86 | /indoleamine | 1 |
87 | /t-helper | 1 |
88 | /type | 1 |
89 | 014.764 | 1 |
90 | 032-59 | 1 |
91 | 1/cycle | 1 |
92 | 1/type | 1 |
93 | 103.1+/-35.2 | 1 |
94 | 114.68-98.84 | 1 |
95 | 16.5-28.2 | 1 |
96 | 16.9±0.9 | 1 |
97 | 20=wup | 1 |
98 | 249±1 | 1 |
99 | 3-month-long | 1 |
100 | 324±3 | 1 |
101 | 36.0±3.2 | 1 |
102 | 478.4 | 1 |
103 | 500-4 | 1 |
104 | 519-3 | 1 |
105 | 590-fed | 1 |
106 | 6.9±3.5 | 1 |
107 | 6:0.011 | 1 |
108 | 6±0.005 | 1 |
109 | 7.9±0.5 | 1 |
110 | 727±2 | 1 |
111 | 74-micrograms | 1 |
112 | 7±0.009 | 1 |
113 | 837±1 | 1 |
114 | 9-0.063 | 1 |
115 | 9-0.098 | 1 |
116 | 9/l-13.8 | 1 |
117 | 908.8,4 | 1 |
118 | 932/3 | 1 |
119 | 972±2 | 1 |
120 | a.m.-1:59 | 1 |
121 | a.m.-8 | 1 |
122 | a=asa+er-dp | 1 |
123 | administration/time | 1 |
124 | and10 | 1 |
125 | and±13 | 1 |
126 | and±31 | 1 |
127 | ascope™ | 1 |
128 | asetonide | 1 |
129 | at6 | 1 |
130 | bar-4 | 1 |
131 | bilateral/10 | 1 |
132 | boars/dietary | 1 |
133 | cidr-treated | 1 |
134 | clemente-prochaska | 1 |
135 | combs-like | 1 |
136 | constant-work-load | 1 |
137 | criterion-a | 1 |
138 | d/wk×6 | 1 |
139 | dibenzopentalenes | 1 |
140 | emulsion-containing | 1 |
141 | enteritis.both | 1 |
142 | ev-5.1 | 1 |
143 | events-approximately | 1 |
144 | fck | 1 |
145 | fluouracil | 1 |
146 | furopyridine-3-one | 1 |
147 | g+ral | 1 |
148 | g/l-h | 1 |
149 | gm/ | 1 |
150 | groups-no | 1 |
151 | group×2 | 1 |
152 | h-21 | 1 |
153 | hours-a | 1 |
154 | huì | 1 |
155 | hz-10 | 1 |
156 | hz-10,000 | 1 |
157 | hz/120 | 1 |
158 | hz/32.4 | 1 |
159 | i.d.x | 1 |
160 | id/2005 | 1 |
161 | innoxious-distracted | 1 |
162 | k/µl | 1 |
163 | kda-0.22 | 1 |
164 | kg/m2.the | 1 |
165 | khz-2 | 1 |
166 | kj/m2 | 1 |
167 | m-650 | 1 |
168 | mapkapk | 1 |
169 | mcg+desogestrel | 1 |
170 | mcg/kgfor | 1 |
171 | mcg/lng | 1 |
172 | mg+amlodipine | 1 |
173 | mg+nebivolol | 1 |
174 | mg+neta | 1 |
175 | mg+v | 1 |
176 | mg-hydrochlorothiazide | 1 |
177 | mg-indapamide | 1 |
178 | mg-norgestimate | 1 |
179 | mg/atorvastatin | 1 |
180 | mg/benazepril | 1 |
181 | mg/caffeine | 1 |
182 | mg/d/4 | 1 |
183 | mg/day+fenofibrate | 1 |
184 | mg/day+guanfacine | 1 |
185 | mg/day±everolimus | 1 |
186 | mg/hc | 1 |
187 | mg/kg-ephedrine | 1 |
188 | mg/kg/day+ta606 | 1 |
189 | mg/lercanidipine | 1 |
190 | mg/m²+cyclophosphamide | 1 |
191 | mg/neta | 1 |
192 | mg/verapamil | 1 |
193 | mg±perindopril | 1 |
194 | mhz∼5 | 1 |
195 | microg-3 | 1 |
196 | microg/fluticasone | 1 |
197 | micrograms/ointment | 1 |
198 | milliseconds/delay | 1 |
199 | mitoses/10 | 1 |
200 | ml-20 | 1 |
201 | mm+lps | 1 |
202 | mm/0.2 | 1 |
203 | mm×0.85 | 1 |
204 | mo/18 | 1 |
205 | months-32.5 | 1 |
206 | months/laser | 1 |
207 | mpa/sintering | 1 |
208 | mu+ | 1 |
209 | nm-1,069.6 | 1 |
210 | nm-100 | 1 |
211 | nm-1000 | 1 |
212 | nm-2.4 | 1 |
213 | nm-20 | 1 |
214 | nm-300 | 1 |
215 | nm-4.35 | 1 |
216 | nm-50 | 1 |
217 | nm-505.4 | 1 |
218 | nm/382.5 | 1 |
219 | nm/4.1 | 1 |
220 | nm/620 | 1 |
221 | no-gwu | 1 |
222 | noxious-attended | 1 |
223 | noxious-distracted | 1 |
224 | nóng | 1 |
225 | ofsensory | 1 |
226 | ons/2 | 1 |
227 | p.m.-2 | 1 |
228 | p.m.-4:59 | 1 |
229 | p.m.-5:30 | 1 |
230 | p.m.-8:00 | 1 |
231 | p.m.-8:59 | 1 |
232 | p3/nsi/1-ag | 1 |
233 | plg/fluticasone | 1 |
234 | pm-1 | 1 |
235 | postmorning-dose | 1 |
236 | power/2-20 | 1 |
237 | prop-alcohol-free | 1 |
238 | pu=10 | 1 |
239 | puffs/nostril | 1 |
240 | radiotherapy-group | 1 |
241 | registrar/consultant | 1 |
242 | risk/type | 1 |
243 | s/110 | 1 |
244 | seconds/10 | 1 |
245 | seconds/7.23 | 1 |
246 | seconds±82.49 | 1 |
247 | set×8-10 | 1 |
248 | sexualidad | 1 |
249 | steps/15 | 1 |
250 | stools/g | 1 |
251 | sufentinil | 1 |
252 | t-1.5 | 1 |
253 | tactical-only | 1 |
254 | taps/10 | 1 |
255 | therapy.at | 1 |
256 | to124 | 1 |
257 | toxicities.the | 1 |
258 | to−1.43 | 1 |
259 | ventilation/6-8 | 1 |
260 | vs.14.89 | 1 |
261 | vs.14.9 | 1 |
262 | was±15 | 1 |
263 | weeks-in | 1 |
264 | weeks-was | 1 |
265 | wooler | 1 |
266 | years-the | 1 |
267 | z,4 | 1 |
268 | ~1.48-1.51 | 1 |
269 | ±.36 | 1 |
270 | ±13.9 | 1 |
271 | ±16·2 | 1 |
272 | ±2.08 | 1 |
273 | ±2.53 | 1 |
274 | ±3.92 | 1 |
275 | µt- | 1 |
276 | µt-100 | 1 |
277 | µt-50 | 1 |
278 | ×1.5 | 1 |
279 | ×700 | 1 |
280 | å=0.1 | 1 |
281 | μev–4.8 | 1 |
282 | μg/ee | 1 |
283 | μg/f | 1 |
284 | μg/kg/glycopyrrolate | 1 |
285 | μm-3.83 | 1 |
286 | μm-85.6 | 1 |
287 | “late | 1 |
288 | ≤15.0 | 1 |
289 | ᅲ | 1 |
1 | +/-18.9 | 1 |
2 | +74.0 | 1 |
3 | +amoxicillin | 2 |
4 | -25385tt | 1 |
5 | -3-alkylideneindolin-2-ones | 1 |
6 | -7,7-dimethyl-5-oxo-4h-chromene-3-carbonitrile | 1 |
7 | -melatonin | 1 |
8 | -o-oleoyl- | 1 |
9 | .phase | 1 |
10 | /dynes | 2 |
11 | /ejection | 2 |
12 | /glycopyrrolate | 1 |
13 | /hapless | 1 |
14 | /indoleamine | 1 |
15 | /t-helper | 1 |
16 | /type | 1 |
17 | 000-1 | 2 |
18 | 014.764 | 1 |
19 | 032-59 | 1 |
20 | 1-type | 2 |
21 | 1/cycle | 1 |
22 | 1/group | 2 |
23 | 1/type | 1 |
24 | 103.1+/-35.2 | 1 |
25 | 114.68-98.84 | 1 |
26 | 16.5-28.2 | 1 |
27 | 16.9±0.9 | 1 |
28 | 2,5-carbodianions | 2 |
29 | 20=wup | 1 |
30 | 249±1 | 1 |
31 | 3-month-long | 1 |
32 | 324±3 | 1 |
33 | 36.0±3.2 | 1 |
34 | 478.4 | 1 |
35 | 486+pg | 2 |
36 | 500-4 | 1 |
37 | 519-3 | 1 |
38 | 590-fed | 1 |
39 | 6.9±3.5 | 1 |
40 | 6:0.011 | 1 |
41 | 6±0.005 | 1 |
42 | 7.9±0.5 | 1 |
43 | 727±2 | 1 |
44 | 74-micrograms | 1 |
45 | 7±0.009 | 1 |
46 | 837±1 | 1 |
47 | 9-0.063 | 1 |
48 | 9-0.098 | 1 |
49 | 9/l-13.8 | 1 |
50 | 908.8,4 | 1 |
51 | 932/3 | 1 |
52 | 972±2 | 1 |
53 | =2.88 | 2 |
54 | a.m.-10 | 2 |
55 | a.m.-1:59 | 1 |
56 | a.m.-8 | 1 |
57 | a=asa+er-dp | 1 |
58 | administration/time | 1 |
59 | and10 | 1 |
60 | and±13 | 1 |
61 | and±31 | 1 |
62 | anti-tarc+100 | 2 |
63 | ascope™ | 1 |
64 | asetonide | 1 |
65 | at6 | 1 |
66 | bar-4 | 1 |
67 | bilateral/10 | 1 |
68 | boars/dietary | 1 |
69 | bresse | 2 |
70 | cidr-treated | 1 |
71 | clemente-prochaska | 1 |
72 | cm/2 | 2 |
73 | cm/6 | 3 |
74 | combs-like | 1 |
75 | constant-work-load | 1 |
76 | criterion-a | 1 |
77 | d/wk×6 | 1 |
78 | dibenzopentalenes | 1 |
79 | dn001 | 2 |
80 | emulsion-containing | 1 |
81 | enteritis.both | 1 |
82 | episodes/10,000 | 4 |
83 | ev-5.1 | 1 |
84 | events-approximately | 1 |
85 | fck | 1 |
86 | fluouracil | 1 |
87 | furopyridine-3-one | 1 |
88 | g+ral | 1 |
89 | g/l-h | 1 |
90 | gm/ | 1 |
91 | groups-an | 2 |
92 | groups-no | 1 |
93 | group×2 | 1 |
94 | h-21 | 1 |
95 | h-driving | 2 |
96 | hours-a | 1 |
97 | huì | 1 |
98 | hz-10 | 1 |
99 | hz-10,000 | 1 |
100 | hz/ | 3 |
101 | hz/100 | 33 |
102 | hz/120 | 1 |
103 | hz/15 | 4 |
104 | hz/20 | 4 |
105 | hz/200 | 2 |
106 | hz/32.4 | 1 |
107 | hz/50 | 2 |
108 | i.d.x | 1 |
109 | id/2005 | 1 |
110 | innoxious-distracted | 1 |
111 | k/µl | 1 |
112 | kda-0.22 | 1 |
113 | kg/8 | 3 |
114 | kg/m2.the | 1 |
115 | khz-2 | 1 |
116 | kj/m2 | 1 |
117 | l-name-epicatechin | 2 |
118 | lx:0.5 | 2 |
119 | m-650 | 1 |
120 | mapkapk | 1 |
121 | mcg+desogestrel | 1 |
122 | mcg/kgfor | 1 |
123 | mcg/lng | 1 |
124 | mft/d | 2 |
125 | mg+amlodipine | 1 |
126 | mg+clopidogrel | 2 |
127 | mg+hyd | 2 |
128 | mg+nebivolol | 1 |
129 | mg+neta | 1 |
130 | mg+v | 1 |
131 | mg-hydrochlorothiazide | 1 |
132 | mg-indapamide | 1 |
133 | mg-norgestimate | 1 |
134 | mg-simvastatin | 4 |
135 | mg/acetaminophen | 8 |
136 | mg/aml | 10 |
137 | mg/amlodipine | 16 |
138 | mg/atorvastatin | 1 |
139 | mg/benazepril | 1 |
140 | mg/benserazide | 2 |
141 | mg/bza | 5 |
142 | mg/caffeine | 1 |
143 | mg/d/4 | 1 |
144 | mg/day+fenofibrate | 1 |
145 | mg/day+guanfacine | 1 |
146 | mg/day±everolimus | 1 |
147 | mg/dienogest | 2 |
148 | mg/dng | 4 |
149 | mg/drospirenone | 5 |
150 | mg/drsp | 2 |
151 | mg/every | 2 |
152 | mg/ezetimibe | 3 |
153 | mg/hc | 1 |
154 | mg/indapamide | 7 |
155 | mg/kg+mid | 3 |
156 | mg/kg-ephedrine | 1 |
157 | mg/kg/day+ta606 | 1 |
158 | mg/lercanidipine | 1 |
159 | mg/lidocaine | 2 |
160 | mg/lisinopril | 2 |
161 | mg/m²+cyclophosphamide | 1 |
162 | mg/neta | 1 |
163 | mg/pio | 6 |
164 | mg/pravastatin | 2 |
165 | mg/rizatriptan | 2 |
166 | mg/simvastatin | 2 |
167 | mg/sumatriptan | 2 |
168 | mg/valsartan | 2 |
169 | mg/verapamil | 1 |
170 | mg±perindopril | 1 |
171 | mhz∼5 | 1 |
172 | microg-3 | 1 |
173 | microg/fluticasone | 1 |
174 | micrograms/ointment | 1 |
175 | milliseconds/delay | 1 |
176 | mitoses/10 | 1 |
177 | miu/mg98 | 2 |
178 | ml-20 | 1 |
179 | mm+lps | 1 |
180 | mm/0.2 | 1 |
181 | mm×0.85 | 1 |
182 | mo/18 | 1 |
183 | months-32.5 | 1 |
184 | months/ | 2 |
185 | months/laser | 1 |
186 | mpa/sintering | 1 |
187 | mu+ | 1 |
188 | n-acetylglucosamine-transferase | 2 |
189 | nm-1 | 3 |
190 | nm-1,069.6 | 1 |
191 | nm-100 | 1 |
192 | nm-1000 | 1 |
193 | nm-2.4 | 1 |
194 | nm-20 | 1 |
195 | nm-300 | 1 |
196 | nm-32.8 | 2 |
197 | nm-4.35 | 1 |
198 | nm-50 | 1 |
199 | nm-505.4 | 1 |
200 | nm/20 | 2 |
201 | nm/382.5 | 1 |
202 | nm/4.1 | 1 |
203 | nm/620 | 1 |
204 | no-gwu | 1 |
205 | noxious-attended | 1 |
206 | noxious-distracted | 1 |
207 | nóng | 1 |
208 | ofsensory | 1 |
209 | ons/2 | 1 |
210 | p.m.-2 | 1 |
211 | p.m.-4:59 | 1 |
212 | p.m.-5:30 | 1 |
213 | p.m.-6 | 2 |
214 | p.m.-8:00 | 1 |
215 | p.m.-8:59 | 1 |
216 | p3/nsi/1-ag | 1 |
217 | plg/fluticasone | 1 |
218 | pm-1 | 1 |
219 | post-addendum | 2 |
220 | postmorning-dose | 1 |
221 | power/2-20 | 1 |
222 | prop-alcohol-free | 1 |
223 | pu=10 | 1 |
224 | puffs/nostril | 1 |
225 | radiotherapy-group | 1 |
226 | registrar/consultant | 1 |
227 | rhtarc+20 | 2 |
228 | risk/type | 1 |
229 | s/110 | 1 |
230 | seconds/10 | 1 |
231 | seconds/7.23 | 1 |
232 | seconds±82.49 | 1 |
233 | set×8-10 | 1 |
234 | sexualidad | 1 |
235 | steps/15 | 1 |
236 | stools/g | 1 |
237 | subjects/ | 2 |
238 | sufentinil | 1 |
239 | t-1.5 | 1 |
240 | t/128 | 3 |
241 | tactical-only | 1 |
242 | taps/10 | 1 |
243 | therapy.at | 1 |
244 | thiazole-4,11-diones | 2 |
245 | to124 | 1 |
246 | toxicities.the | 1 |
247 | to−1.43 | 1 |
248 | ventilation/6-8 | 1 |
249 | vs.14.89 | 1 |
250 | vs.14.9 | 1 |
251 | vs.low-dose | 2 |
252 | w/100 | 8 |
253 | w/3 | 2 |
254 | was±15 | 1 |
255 | weeks-in | 1 |
256 | weeks-was | 1 |
257 | wk-1 | 3 |
258 | wk-6 | 2 |
259 | wooler | 1 |
260 | years-the | 1 |
261 | yù | 2 |
262 | z,4 | 1 |
263 | ~1.48-1.51 | 1 |
264 | °p-timi | 2 |
265 | ±.36 | 1 |
266 | ±13.9 | 1 |
267 | ±16·2 | 1 |
268 | ±2.08 | 1 |
269 | ±2.53 | 1 |
270 | ±3.92 | 1 |
271 | µt- | 1 |
272 | µt-100 | 1 |
273 | µt-50 | 1 |
274 | × | 6,709 |
275 | ×/daily | 2 |
276 | ×1.5 | 1 |
277 | ×700 | 1 |
278 | å=0.1 | 1 |
279 | μev–4.8 | 1 |
280 | μg/ee | 1 |
281 | μg/f | 1 |
282 | μg/kg/glycopyrrolate | 1 |
283 | μm-3.83 | 1 |
284 | μm-85.6 | 1 |
285 | х | 2 |
286 | “late | 1 |
287 | ∶ | 4 |
288 | ≤15.0 | 1 |
289 | ᅲ | 1 |
1 | mu+ | 1 |
2 | -o-oleoyl- | 1 |
3 | µt- | 1 |
4 | gm/ | 1 |
5 | months/ | 2 |
6 | subjects/ | 2 |
7 | hz/ | 3 |
8 | +74.0 | 1 |
9 | ≤15.0 | 1 |
10 | hz-10,000 | 1 |
11 | episodes/10,000 | 4 |
12 | nm-1000 | 1 |
13 | anti-tarc+100 | 2 |
14 | nm-100 | 1 |
15 | µt-100 | 1 |
16 | w/100 | 8 |
17 | hz/100 | 33 |
18 | hz/200 | 2 |
19 | nm-300 | 1 |
20 | ×700 | 1 |
21 | p.m.-8:00 | 1 |
22 | a.m.-10 | 2 |
23 | set×8-10 | 1 |
24 | hz-10 | 1 |
25 | bilateral/10 | 1 |
26 | seconds/10 | 1 |
27 | mitoses/10 | 1 |
28 | taps/10 | 1 |
29 | s/110 | 1 |
30 | pu=10 | 1 |
31 | and10 | 1 |
32 | rhtarc+20 | 2 |
33 | power/2-20 | 1 |
34 | ml-20 | 1 |
35 | nm-20 | 1 |
36 | nm/20 | 2 |
37 | hz/20 | 4 |
38 | hz/120 | 1 |
39 | nm/620 | 1 |
40 | p.m.-5:30 | 1 |
41 | nm-50 | 1 |
42 | µt-50 | 1 |
43 | hz/50 | 2 |
44 | m-650 | 1 |
45 | 000-1 | 2 |
46 | wk-1 | 3 |
47 | nm-1 | 3 |
48 | pm-1 | 1 |
49 | å=0.1 | 1 |
50 | nm/4.1 | 1 |
51 | ev-5.1 | 1 |
52 | dn001 | 2 |
53 | 6:0.011 | 1 |
54 | h-21 | 1 |
55 | and±31 | 1 |
56 | ~1.48-1.51 | 1 |
57 | 837±1 | 1 |
58 | 249±1 | 1 |
59 | p.m.-2 | 1 |
60 | khz-2 | 1 |
61 | mm/0.2 | 1 |
62 | 36.0±3.2 | 1 |
63 | 103.1+/-35.2 | 1 |
64 | 16.5-28.2 | 1 |
65 | cm/2 | 2 |
66 | ons/2 | 1 |
67 | kda-0.22 | 1 |
68 | ±3.92 | 1 |
69 | kj/m2 | 1 |
70 | group×2 | 1 |
71 | 972±2 | 1 |
72 | 727±2 | 1 |
73 | ±16·2 | 1 |
74 | 519-3 | 1 |
75 | microg-3 | 1 |
76 | 932/3 | 1 |
77 | w/3 | 2 |
78 | and±13 | 1 |
79 | seconds/7.23 | 1 |
80 | to−1.43 | 1 |
81 | ±2.53 | 1 |
82 | 9-0.063 | 1 |
83 | μm-3.83 | 1 |
84 | 324±3 | 1 |
85 | 908.8,4 | 1 |
86 | z,4 | 1 |
87 | 500-4 | 1 |
88 | bar-4 | 1 |
89 | nm-2.4 | 1 |
90 | hz/32.4 | 1 |
91 | nm-505.4 | 1 |
92 | 478.4 | 1 |
93 | mg/d/4 | 1 |
94 | to124 | 1 |
95 | 014.764 | 1 |
96 | 114.68-98.84 | 1 |
97 | lx:0.5 | 2 |
98 | 7.9±0.5 | 1 |
99 | t-1.5 | 1 |
100 | ×1.5 | 1 |
101 | months-32.5 | 1 |
102 | nm/382.5 | 1 |
103 | 6.9±3.5 | 1 |
104 | 6±0.005 | 1 |
105 | id/2005 | 1 |
106 | steps/15 | 1 |
107 | hz/15 | 4 |
108 | was±15 | 1 |
109 | nm-4.35 | 1 |
110 | mm×0.85 | 1 |
111 | mhz∼5 | 1 |
112 | p.m.-6 | 2 |
113 | wk-6 | 2 |
114 | μm-85.6 | 1 |
115 | nm-1,069.6 | 1 |
116 | cm/6 | 3 |
117 | mg/kg/day+ta606 | 1 |
118 | ±.36 | 1 |
119 | at6 | 1 |
120 | d/wk×6 | 1 |
121 | a.m.-8 | 1 |
122 | ventilation/6-8 | 1 |
123 | nm-32.8 | 2 |
124 | 9/l-13.8 | 1 |
125 | μev–4.8 | 1 |
126 | kg/8 | 3 |
127 | ±2.08 | 1 |
128 | mo/18 | 1 |
129 | t/128 | 3 |
130 | =2.88 | 2 |
131 | 9-0.098 | 1 |
132 | miu/mg98 | 2 |
133 | 16.9±0.9 | 1 |
134 | ±13.9 | 1 |
135 | vs.14.9 | 1 |
136 | +/-18.9 | 1 |
137 | 7±0.009 | 1 |
138 | seconds±82.49 | 1 |
139 | 032-59 | 1 |
140 | a.m.-1:59 | 1 |
141 | p.m.-4:59 | 1 |
142 | p.m.-8:59 | 1 |
143 | vs.14.89 | 1 |
144 | criterion-a | 1 |
145 | hours-a | 1 |
146 | clemente-prochaska | 1 |
147 | mg+neta | 1 |
148 | mg/neta | 1 |
149 | mg/bza | 5 |
150 | mg/hc | 1 |
151 | mft/d | 2 |
152 | sexualidad | 1 |
153 | constant-work-load | 1 |
154 | noxious-attended | 1 |
155 | 590-fed | 1 |
156 | cidr-treated | 1 |
157 | noxious-distracted | 1 |
158 | innoxious-distracted | 1 |
159 | mg/kg+mid | 3 |
160 | mg+hyd | 2 |
161 | mg/ezetimibe | 3 |
162 | mg/m²+cyclophosphamide | 1 |
163 | mg-indapamide | 1 |
164 | mg/indapamide | 7 |
165 | asetonide | 1 |
166 | mg-hydrochlorothiazide | 1 |
167 | mg/benserazide | 2 |
168 | μg/ee | 1 |
169 | prop-alcohol-free | 1 |
170 | years-the | 1 |
171 | kg/m2.the | 1 |
172 | toxicities.the | 1 |
173 | combs-like | 1 |
174 | 1/cycle | 1 |
175 | -7,7-dimethyl-5-oxo-4h-chromene-3-carbonitrile | 1 |
176 | administration/time | 1 |
177 | mg/lidocaine | 2 |
178 | mg/day+guanfacine | 1 |
179 | mg/caffeine | 1 |
180 | /indoleamine | 1 |
181 | mg/lercanidipine | 1 |
182 | mg+amlodipine | 1 |
183 | mg/amlodipine | 16 |
184 | mg/kg-ephedrine | 1 |
185 | furopyridine-3-one | 1 |
186 | mg/drospirenone | 5 |
187 | plg/fluticasone | 1 |
188 | microg/fluticasone | 1 |
189 | 1-type | 2 |
190 | /type | 1 |
191 | 1/type | 1 |
192 | risk/type | 1 |
193 | .phase | 1 |
194 | n-acetylglucosamine-transferase | 2 |
195 | postmorning-dose | 1 |
196 | vs.low-dose | 2 |
197 | bresse | 2 |
198 | /glycopyrrolate | 1 |
199 | μg/kg/glycopyrrolate | 1 |
200 | “late | 1 |
201 | mg-norgestimate | 1 |
202 | mg/day+fenofibrate | 1 |
203 | μg/f | 1 |
204 | stools/g | 1 |
205 | p3/nsi/1-ag | 1 |
206 | mg/dng | 4 |
207 | emulsion-containing | 1 |
208 | mpa/sintering | 1 |
209 | h-driving | 2 |
210 | mcg/lng | 1 |
211 | 3-month-long | 1 |
212 | nóng | 1 |
213 | 486+pg | 2 |
214 | g/l-h | 1 |
215 | enteritis.both | 1 |
216 | °p-timi | 2 |
217 | fck | 1 |
218 | mapkapk | 1 |
219 | g+ral | 1 |
220 | mg+clopidogrel | 2 |
221 | mcg+desogestrel | 1 |
222 | fluouracil | 1 |
223 | mg/verapamil | 1 |
224 | sufentinil | 1 |
225 | mg/benazepril | 1 |
226 | mg±perindopril | 1 |
227 | mg/lisinopril | 2 |
228 | puffs/nostril | 1 |
229 | mg/aml | 10 |
230 | mg+nebivolol | 1 |
231 | k/µl | 1 |
232 | post-addendum | 2 |
233 | groups-an | 2 |
234 | mg/sumatriptan | 2 |
235 | mg/rizatriptan | 2 |
236 | mg/valsartan | 2 |
237 | mg/acetaminophen | 8 |
238 | weeks-in | 1 |
239 | l-name-epicatechin | 2 |
240 | +amoxicillin | 2 |
241 | -melatonin | 1 |
242 | mg/pravastatin | 2 |
243 | mg-simvastatin | 4 |
244 | mg/simvastatin | 2 |
245 | mg/atorvastatin | 1 |
246 | /ejection | 2 |
247 | mg/pio | 6 |
248 | groups-no | 1 |
249 | a=asa+er-dp | 1 |
250 | mg/drsp | 2 |
251 | radiotherapy-group | 1 |
252 | 1/group | 2 |
253 | 20=wup | 1 |
254 | wooler | 1 |
255 | /t-helper | 1 |
256 | months/laser | 1 |
257 | mcg/kgfor | 1 |
258 | weeks-was | 1 |
259 | dibenzopentalenes | 1 |
260 | -3-alkylideneindolin-2-ones | 1 |
261 | thiazole-4,11-diones | 2 |
262 | /dynes | 2 |
263 | 74-micrograms | 1 |
264 | 2,5-carbodianions | 2 |
265 | mm+lps | 1 |
266 | /hapless | 1 |
267 | mg/day±everolimus | 1 |
268 | therapy.at | 1 |
269 | registrar/consultant | 1 |
270 | micrograms/ointment | 1 |
271 | mg/dienogest | 2 |
272 | -25385tt | 1 |
273 | no-gwu | 1 |
274 | mg+v | 1 |
275 | i.d.x | 1 |
276 | milliseconds/delay | 1 |
277 | events-approximately | 1 |
278 | ×/daily | 2 |
279 | tactical-only | 1 |
280 | boars/dietary | 1 |
281 | mg/every | 2 |
282 | ofsensory | 1 |
283 | х | 2 |
284 | ᅲ | 1 |
285 | × | 6,709 |
286 | ascope™ | 1 |
287 | huì | 1 |
288 | ∶ | 4 |
289 | yù | 2 |